Bicardef

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bicardef

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablet
Pharmacological class Cardioselective Beta-blocker (beta1-selective)
General purpose Reduces cardiovascular strain
Origin Synthetic

What Type of Medicine is Bicardef?

Bicardef is a synthetic, prescription-only pharmaceutical preparation that belongs to the therapeutic class of beta-blockers, officially classified as an adrenergic beta-antagonist. Its active chemical compound is bisoprolol fumarate, a substance recognized for its high degree of cardioselectivity. Due to this property, the medicine acts primarily on the heart's beta1-receptors. Bicardef is typically positioned toward adults requiring focused, long-term cardiovascular management. The medication is formulated as a single-agent product for oral administration and is consistently presented as a film-coated tablet.


Composition and Selectivity of Bisoprolol

Bicardef's therapeutic effect is derived from its single, active component, bisoprolol fumarate. The significance of its beta1-selectivity lies in its preferential action on receptors found predominantly in the heart tissue. This selective action provides a focused mechanism for managing heart function while minimizing interaction with beta2 receptors located in non-cardiac tissues, such as the lungs. This design is central to its utility, as bisoprolol is clinically recognized for its efficacy and potency compared to some non-selective older generation agents.


Bicardef's General Therapeutic Purpose

The fundamental purpose of Bicardef is to reduce mechanical stress on the cardiovascular system by modulating the heart's activity. Its selective blockade helps to decrease both the heart rate and the force with which the heart contracts. This controlled reduction in cardiac output makes the heart's function more energy-efficient and achieves a more stable state throughout the circulatory system. Bisoprolol is a highly selective beta1-adrenoceptor antagonist used in the management of cardiovascular conditions. The medication reduces the heart's workload by decreasing its oxygen consumption, providing a benefit to patients requiring sustained hemodynamic stability.

What side effects are possible with Bicardef?

Possible Side Effects and Safety Information

This information describes the possible adverse reactions and safety constraints for Bicardef (containing bisoprolol), as documented in official government regulatory sources.

Adverse Reactions by Frequency

Adverse reactions are classified by how often they occur, based on clinical data:

  • Common (1% to 10%): Slowed heart rate (bradycardia), feeling tired (fatigue), dizziness, headache, and feeling cold in the hands and feet. Gastrointestinal issues like nausea, diarrhea, or constipation may also occur.
  • Uncommon (0.1% to 1%): Sleep disorders, depression, muscular weakness, and difficulties with heart rhythm (AV conduction disturbances).
  • Rare (0.01% to 0.1%): Nightmares, hallucinations, and elevated liver enzymes. Allergic reactions such as rash and pruritus are also documented in this category.

Serious Safety Considerations

The medicine is associated with risks requiring immediate attention, including the worsening or precipitation of heart failure and severe bronchospasm in susceptible individuals. A major safety restriction is the requirement that Bicardef must not be stopped suddenly; abrupt discontinuation can lead to severe chest pain (angina) or heart attack, particularly in patients with pre-existing coronary artery disease. A dose reduction (tapering) is officially mandated.

Population-Specific Safety Notes

The official label contains specific information for certain groups:

  • Heart Failure: Use is restricted to patients with stable, chronic heart failure, requiring gradual dose increases.
  • Diabetic Patients: Bicardef may mask the physical signs of low blood sugar (hypoglycemia), necessitating regular blood glucose monitoring.
  • Renal/Hepatic Impairment: Requires caution and potential dose adjustment due to altered drug clearance.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Bicardef (a beta-blocker) by its potential for severe, life-threatening effects primarily involving the cardiovascular and central nervous systems. Overdosage, particularly with supratherapeutic doses, requires immediate, urgent medical intervention.

Documented Overdose Manifestations

The most serious signs of overdose include severe bradycardia (abnormally slow heart rate), profound hypotension (dangerously low blood pressure), second- or third-degree atrioventricular block, and symptoms of heart failure. Systemic effects can involve bronchospasm, severe weakness, and central nervous system depression leading to convulsions or coma.

When to Seek Immediate Medical Help

Any suspected overdose with Bicardef, or the presentation of these severe symptoms, necessitates immediate contact with emergency medical services or a Poison Control Center. Do not wait for symptoms to worsen before seeking urgent professional help.

Overdose Management and Monitoring

Official management instructions focus on supportive and symptomatic treatment. Healthcare providers are instructed to monitor vital signs and perform continuous electrocardiogram (ECG) monitoring. Pharmacologic agents such as intravenous atropine and glucagon are officially documented for use in managing specific cardiac toxicities. Activated charcoal may be administered to reduce systemic absorption. Hypoglycemia, particularly in children, is a documented risk that requires specific monitoring and treatment.

Therapeutic Uses of Bicardef

Bicardef is commonly used in the long-term management of cardiovascular conditions, supporting patients with conditions characterized by noticeable physiological strain.

The medication is relevant for easing symptomatic burden in three main therapeutic areas: high blood pressure (hypertension), chronic stable angina (symptoms related to physical discomfort), and stable chronic heart failure.

Symptomatic Relief and Patient Support

Bicardef is generally used for managing symptoms related to systemic imbalance and heightened physiological activity, especially in conditions involving episodic or fluctuating manifestations. It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability. Its use in these conditions is focused on supportive symptom management, helping to ease the overall symptom load and maintain functional stability of the heart.

“It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Support for Systemic Imbalance

Bicardef helps ease the overall symptom load associated with conditions marked by increased physiological stress and contributes to improved comfort during symptomatic phases.

Eligibility and Restrictions for Use

Bicardef is officially permitted for adults managing hypertension, stable angina pectoris, or stable chronic heart failure. Use is strictly prohibited (contraindicated) in patients with severe conditions including cardiogenic shock, overt cardiac failure, second or third-degree AV block, and marked sinus bradycardia. Other absolute non-eligibility rules cover severe bronchial asthma and untreated phaeochromocytoma.

The medicine is not recommended for the pediatric population (under 18) because safety and efficacy have not been established. Older adults are eligible without dose adjustment based on age alone. Patients with severe renal or hepatic impairment are eligible only under restricted conditions, as the maximum authorized daily dose is limited. Regulatory documents state the medicine should be used during pregnancy only if no alternatives exist and is not preferred while breastfeeding newborns. Caution is required for patients with diabetes mellitus or other bronchospastic diseases, as the medicine may mask symptoms.

What should I know about interactions with other medicines?

The regulatory profile for Bicardef (Bisoprolol fumarate) defines interactions based on the potential for additive effects and specific restrictions documented in official labels.

Official Interaction Restrictions

Combinations with Floctafenine and Sultopride are classified as contraindicated in official prescribing information due to documented risks, including ventricular arrhythmia. The co-administration of Bicardef with other beta-blocking agents is also restricted due to the potential for excessive reduction of sympathetic activity.

Documented Pharmacodynamic Effects

Pharmacodynamic interactions frequently result in additive effects on cardiovascular function. The combination with Calcium antagonists of the verapamil or diltiazem type may significantly increase the risk of severe bradycardia and hypotension. Similarly, Class I antiarrhythmic drugs are noted to potentiate the effect on atrioventricular conduction time. Conversely, NSAIDs, such as ibuprofen, may reduce the expected blood pressure-lowering effect through pharmacodynamic antagonism.

Procedural and Population Constraints

A specific mandatory sequential rule applies to Centrally-acting Antihypertensives: if therapy involving Clonidine is to be discontinued, Bicardef must be stopped for several days before the withdrawal of Clonidine. Pharmacokinetic data indicates that Rifampicin may slightly reduce bisoprolol plasma concentrations. A population-specific consideration notes that Bicardef's plasma half-life is increased approximately threefold in patients with severe renal impairment ( creatinine clearance < 40 mL/min).

Mechanism of Action

How Bicardef Works — Mechanism of Action

Bicardef is a competitive antagonist acting primarily on beta1-adrenergic receptors (beta1-ARs) located mainly on myocardial cells and the cardiac conduction system. Its mechanism initiates with the physical blockade of these receptors, preventing the binding of endogenous catecholamines, such as norepinephrine.

This interaction interrupts the Gs-protein signaling cascade. The subsequent failure to activate the enzyme adenylyl cyclase results in reduced production of the intracellular messenger cyclic AMP ( cAMP) and, consequently, lower activity of Protein Kinase A ( PKA).

The overall cellular consequence is a reduction in the phosphorylation of calcium-handling proteins, leading to a diminished availability of intracellular Ca^2+. At the physiological level, this produces negative chronotropy (decreased heart rate) and negative inotropy (decreased contractility), reducing cardiac work and oxygen consumption. These adjustments ultimately result in a modulation of cardiac electrical pacing and lower arterial blood pressure.

Dosage and Administration Information

How Bicardef is Used

Bicardef (bisoprolol fumarate) is administered exclusively by the oral route as a film-coated tablet, following a once-daily dosing schedule, preferably taken in the morning. The tablets should be swallowed whole with water and can be taken either with or without food.


Dosing Protocol and Administration Constraints

Dosing protocols vary based on the treated condition. For high blood pressure (hypertension) or stable angina, treatment typically begins at 5 mg once daily, with a maximum dose of 20 mg once daily.

In contrast, management of stable chronic heart failure requires a significantly lower initial dose of 1.25 mg once daily. This dose is then gradually increased, or titrated, over several weeks, with the maximum recommended daily dose not exceeding 10 mg. This controlled titration must occur when the patient is clinically stable.

Population-Specific Use and Cessation

For patients with severe impairment of kidney or liver function, the daily dose generally must not exceed 10 mg. The medication is not recommended for use in pediatric patients due to a lack of established dosing data.

If treatment with Bicardef is to be discontinued, the dose must not be stopped abruptly. Instead, the dose should be gradually reduced over a period of approximately one to two weeks to prevent potential acute episodes. If a dose is missed, it should be taken as soon as remembered that same day, but a double dose must be avoided by skipping it if it is near the next scheduled time.

Recent Clinical Evidence

This section provides an objective overview of the clinical research conducted on Bicardef (Bisoprolol Fumarate), focusing only on the structure of the available evidence without making any claims about effectiveness or providing clinical advice.

Evidence for Use in Chronic Stable Heart Failure

The core evidence for this condition was derived from large-scale Randomized Controlled Trials (RCTs). This research was studied for conditions marked by functional limitations and systemic imbalance, focusing on tracking major event rates like all-cause mortality and hospitalization rates. These studies primarily included adults with reduced systolic function, typically studied while also receiving baseline concurrent therapies. Limited research exists for patients with Heart Failure with Preserved Ejection Fraction (HFpEF) or those in phases of acute instability.


Evidence for Use in High Blood Pressure (Hypertension)

Evidence for high blood pressure was primarily evaluated in RCTs and systematic reviews. These studies monitored physiological strain, specifically measuring systolic and diastolic blood pressure readings and changes in heart rate over short-term to intermediate-term intervals. Studies described patterns related to measured changes in blood pressure, and comparative research describes relative changes when Bicardef was compared to other active comparator agents.


Evidence for Use in Chronic Stable Angina Pectoris

Research for chronic stable angina was studied for outcomes related to physical discomfort and activity level, such as anginal frequency and exercise capacity. Findings describe patterns observed in the studies regarding symptomatic response, contributing to the broader evidence landscape. Comparative evidence is lacking when its use as a single agent is compared to its use in combination with other anti-anginal therapies.


Evidence Scope: Duration and Specific Groups

Research examined effects over follow-up periods that range from several weeks up to several years. For many outcomes, however, follow-up durations were limited, and long-term effects are not fully established. Studies explored how the medication was evaluated in specific groups, including older adults and different levels of heart failure severity. Data for certain groups remain insufficient, particularly for children or pregnant populations.


The Research Landscape: Gaps and Uncertainties

The research landscape was studied for key indications, but certain areas remain open to further exploration. Evidence is limited for long-term outcomes in some populations, and subgroup findings are uncertain. Remember, research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Bicardef (FAQ)


Q: How quickly is Bicardef supposed to start working?

The maximal effect of the active ingredient on heart rate was described in studies as occurring within one to four hours after taking the tablet. When used for high blood pressure, reductions in blood pressure readings were often noted within one week of initiating treatment, according to regulatory documents.


Q: What is the difference between Bicardef and other similar-sounding heart medications?

Bicardef contains bisoprolol fumarate, which is officially classified as a cardioselective beta-1 (β1) blocker. This means the medication is designed to act primarily on the heart's receptors. This feature is the main classification detail that differentiates it from non-selective beta-blockers or other classes of heart medicine.


Q: Can I drink alcohol while I am taking Bicardef?

Regulatory guidance suggests that combining Bicardef with alcohol (ethanol) can result in additive effects that further lower blood pressure. Official guidance indicates this combination may increase the potential for side effects such as dizziness, lightheadedness, or headache. This risk is often higher when treatment is initiated or doses are adjusted.


Q: Is there a risk of interaction if I take Bicardef with herbal supplements?

Official information indicates there is limited specific data available regarding interactions between Bicardef and many herbal remedies or supplements. Official information suggests informing a healthcare provider about any supplements being used due to the possibility of unknown interaction risks.


Q: Are there certain foods or drinks I should avoid while taking Bicardef?

According to the official product information, the absorption of the active ingredient in Bicardef is not significantly affected by food. Therefore, the medication can be taken either with or without food.


Q: How long do people usually need to take Bicardef for?

Treatment with Bicardef, especially for chronic conditions like high blood pressure or heart failure, is typically described in official documents as being for the long term. It is often required for an extended period to manage the underlying condition.


Q: Does Bicardef cure the condition, or just manage the symptoms?

Bicardef is officially indicated for the treatment and management of conditions such as high blood pressure and stable chronic heart failure. This classification refers to the ongoing control of symptoms and cardiovascular strain, rather than a permanent cure of the underlying disease.


Q: Is there a generic version of Bicardef available?

Yes, the active chemical compound in Bicardef, bisoprolol fumarate, is listed in regulatory databases and is available as a generic medication.


Q: Can I take Bicardef with my multivitamins?

Some regulatory resources suggest that certain multivitamins that contain minerals may potentially decrease the intended effect of Bicardef. Official information may suggest separating the administration times of these products.


Q: Does Bicardef cause weight gain?

Official safety summaries note that sudden weight gain can be a symptom of a serious concern, such as worsening heart failure. However, general, non-specific weight gain is not explicitly listed as a common or frequent side effect in the adverse reaction listings of core regulatory documents.


Q: How does Bicardef affect cholesterol levels?

Clinical studies have examined the effects of the active ingredient on serum lipids. Official documentation notes that the medication had minimal effects on total cholesterol and triglycerides during clinical trials, with changes comparable to those seen with a placebo.


Q: Is there a maximum time someone can be on Bicardef?

Official patient information describes treatment with Bicardef as typically being for the long term, suggesting that there is no predetermined maximum time limit for use. Continued use is generally described as being appropriate for the ongoing management of the condition.


Q: Can taking Bicardef affect my ability to drive or operate machinery?

Regulatory patient leaflets caution that Bicardef may cause side effects such as tiredness, dizziness, or lightheadedness. Individuals should observe how the medicine affects them before driving or operating machinery, particularly when treatment is started or the dose is increased.


Q: Does Bicardef thin the blood?

Bicardef is a beta-blocker that affects the heart and circulation. Interaction studies showed the active ingredient had no effect on prothrombin time in patients taking warfarin (a blood thinner), which suggests it is not classified as a blood-thinning agent.


Q: Can Bicardef cause problems with sexual function?

Problems with sexual function, such as changes in libido or performance, are described in regulatory documents as a potential adverse effect associated with the use of Bicardef.


Q: Does Bicardef affect the immune system?

Official documentation notes a precaution regarding the risk of severe hypersensitivity reactions (allergic reactions). It is noted that patients taking beta-blockers may be less responsive to the effects of epinephrine, which is used to treat such reactions.


Q: How do regulatory bodies classify the safety profile of Bicardef?

Regulatory bodies describe the safety profile by detailing contraindications and use in special populations. For example, the active ingredient is classified by some authorities based on findings from animal studies regarding potential effects on a fetus.


Q: What is the difference in purpose between Bicardef and a diuretic?

Bicardef's official purpose is based on its classification as a beta-blocker, which works by modulating heart activity to reduce cardiac strain and lower blood pressure. In contrast, diuretics work primarily by causing the kidneys to excrete more salt and water from the body.


Q: Is Bicardef suitable for use by athletes?

The active ingredient in Bicardef, bisoprolol, is classified by the World Anti-Doping Agency (WADA) as a prohibited substance in specific competitive sports (such as archery and shooting) when used in competition. This classification means its use is restricted in those particular disciplines.


Q: Does Bicardef interact with vaccines or injections?

Official documentation notes that patients taking beta-blockers may be less responsive to the effects of epinephrine (adrenaline). Epinephrine is sometimes contained in other injections or used to treat severe allergic reactions, and this is a point of caution noted in regulatory materials.


Q: Does Bicardef have any long-term effects on the body?

Official safety summaries highlight the potential for risks associated with long-term use and abrupt withdrawal of the medication. For patients with pre-existing coronary artery disease, suddenly stopping the medication can potentially worsen angina or cause a heart attack, which is why a dose reduction (tapering) is officially required.


Q: Can women who are planning pregnancy use Bicardef?

Regulatory advice suggests that the use of this medication should be reviewed by a healthcare specialist at the earliest opportunity when planning pregnancy. Official labeling notes that use during pregnancy is advised only if the potential benefit outweighs the potential risk to the fetus.


Q: Do you need to have regular blood tests while on Bicardef?

Official patient safety information advises that individuals being treated for diabetes should monitor their blood sugar level regularly, as Bicardef can mask the signs of low blood sugar. The need for other regular blood tests is determined by the patient's specific health condition and the factors being monitored.


Q: Why do official documents mention 'renal impairment' as a consideration for Bicardef use?

The reason is pharmacokinetic: official documents state that the half-life of the drug—the time it takes for the concentration to reduce by half—is increased approximately three-fold in individuals with severe kidney impairment. This requires caution and dose restriction to manage the higher levels of the medication in the body.


Q: What types of heart rhythm issues is Bicardef described as helping with?

Bicardef is officially indicated for conditions like stable angina pectoris and stable chronic heart failure. Its mechanism involves adjusting the heart's electrical pacing, and it may be used to help manage conditions such as Supraventricular Tachycardia, as noted in related regulatory treatment guides.


Q: Are there different strengths or formulations of Bicardef?

Yes, Bicardef is officially available in multiple tablet strengths, which typically include 1.25 mg, 2.5 mg, 5 mg, and 10 mg film-coated tablets. The specific tablets available may feature a score line to allow for halving, depending on the strength and manufacturer.


Q: Are there specific symptoms that warrant immediate consultation while on Bicardef?

Official safety summaries identify conditions such as the worsening of heart failure as serious. Symptoms that may warrant immediate consultation, as described in patient information, include new or increased shortness of breath, swelling of the ankles or feet, and rapid, sudden weight gain.


Q: How do patients generally feel after starting Bicardef?

While individual experiences vary, the most common reported side effects, especially in the first few weeks of treatment, include fatigue, dizziness, and headache. These effects are generally classified as common, affecting between 1% and 10% of patients.


Q: What happens if a pregnant person takes Bicardef?

Official warnings note that beta-blocking agents are associated with potential effects on the fetus, such such as decreased blood flow to the placenta. If the medication is used near the time of delivery, regulatory advice is that the newborn should be monitored for signs of beta-blockade, such as a slow heart rate.

How should Bicardef be stored and disposed of?

Bicardef tablets must be stored under specific conditions to maintain their stability, as required by regulatory authorities.

Storage Requirements

  • Temperature: Store the tablets at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Excursions between 15 C and 30 C (59 F and 86 F) are generally permitted.
  • Protection: The product must be kept in its original container to protect it from moisture and light.
  • Child Safety: In alignment with official labeling, the medicine must be stored out of the sight and reach of children.
  • In-Use Stability: For some high-count bottle packs, the product is stable for 6 months after first opening, provided it is stored below 25 C.

Disposal Instructions

  • Any unused or expired Bicardef product must be disposed of in accordance with local requirements for pharmaceutical waste.
  • The tablets must not be disposed of via wastewater systems or household trash unless specifically directed by local waste management officials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bicardef found in:

A-Z Index: